{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T01:50:03Z","timestamp":1781229003129,"version":"3.54.1"},"reference-count":72,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:p>Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of death. Although statins are the foundation of lipid-lowering therapy, many high-risk patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets due to intolerance or insufficient response. Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors have emerged as potent agents that address this residual risk. This review summarizes the clinical efficacy, safety, and mechanistic role of PCSK9 inhibitors in cardiovascular risk reduction. Relevant randomized trials, meta-analyses, and observational studies were analyzed, alongside emerging nonstatin therapies including bempedoic acid, inclisiran, and Angiopietin-like 3 inhibitors. PCSK9 inhibitors, such as alirocumab and evolocumab, have shown LDL-C reductions of up to 62% and significant decreases in major adverse cardiovascular events. Trials like Further cardiovascular outcomes research with PCSK9 inhibition in subjects With elevated risk (FOURIER) and Evaluation of cardiovascular outcomes after an acute coronary syndrome during treatment with alirocumab (ODYSSEY OUTCOMES) reported relative risk reductions of 15\u201324% in select populations. These agents also reduce lipoprotein(a) (Lp(a)) and stabilize atherosclerotic plaques. Additional therapies like inclisiran and bempedoic acid further expand treatment options, particularly for statin-intolerant patients. PCSK9 inhibitors offer a well-tolerated and effective approach to lowering LDL-C and mitigating cardiovascular risk. Their integration, along with emerging therapies, provides a comprehensive strategy to address residual ASCVD risk and improve patient outcomes. This review highlights the pivotal role of PCSK9 inhibitors in achieving significant LDL-C reduction and improving cardiovascular outcomes, especially in high-risk and statin-intolerant populations. By also targeting Lp(a) and promoting plaque stabilization, these agents address multiple contributors to residual ASCVD risk. Incorporating PCSK9 inhibitors and emerging nonstatin therapies into clinical practice offers a powerful strategy to enhance long-term cardiovascular prevention.<\/jats:p>","DOI":"10.1097\/mca.0000000000001574","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T10:01:26Z","timestamp":1758794486000},"page":"696-706","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Advancements in lipid-lowering therapy: the role of proprotein convertase subtilisin\/kexin type 9 inhibitors and beyond in cardiovascular risk reduction"],"prefix":"10.1097","volume":"36","author":[{"given":"Namita","family":"Ruhela","sequence":"first","affiliation":[{"name":"Department of Medicine, Aureus University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Singla","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Northwest Health, Valparaiso, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yash Vardhan","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jawaharlal Nehru Medical College, Ajmer, Rajasthan, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monami","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College for Women and Hospital, Dhaka, Bangladesh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Chikatimalla","sequence":"additional","affiliation":[{"name":"Department of Medicine, Kamineni Institute of Medical Sciences, Narketpally, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Barnard College of Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"R1-20251101","doi-asserted-by":"crossref","first-page":"7910","DOI":"10.3390\/ijms24097910","article-title":"Atherosclerosis and inflammation: insights from the theory of general pathological processes.","volume":"24","author":"Gusev","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R2-20251101","doi-asserted-by":"crossref","first-page":"100633","DOI":"10.1016\/j.ajpc.2024.100633","article-title":"Global burden of cardiovascular diseases attributed to low physical activity: an analysis of 204 countries and territories between 1990 and 2019.","volume":"17","author":"Luo","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"R3-20251101","first-page":"100201","article-title":"Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA\/ACC multi-society cholesterol guideline.","volume":"21","author":"Alanaeme","year":"2022","journal-title":"Am Heart J Plus"},{"key":"R4-20251101","doi-asserted-by":"crossref","first-page":"100025","DOI":"10.1016\/j.medntd.2019.100025","article-title":"Gender differences in cardiovascular disease.","volume":"4","author":"Gao","year":"2019","journal-title":"Med Nov Technol Devices"},{"key":"R5-20251101","doi-asserted-by":"crossref","first-page":"117268","DOI":"10.1016\/j.atherosclerosis.2023.117268","article-title":"Sex differences in the management of atherosclerotic cardiovascular disease.","volume":"384","author":"Holtzman","year":"2023","journal-title":"Atherosclerosis"},{"key":"R6-20251101","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1161\/CIRCULATIONAHA.116.022194","article-title":"Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus - mechanisms, management, and clinical considerations.","volume":"133","author":"Low Wang","year":"2016","journal-title":"Circulation"},{"key":"R7-20251101","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3390\/molecules28030969","article-title":"Lipoprotein(a) in atherosclerotic diseases: from pathophysiology to diagnosis and treatment.","volume":"28","author":"Lampsas","year":"2023","journal-title":"Molecules"},{"key":"R8-20251101","doi-asserted-by":"crossref","first-page":"161","DOI":"10.34172\/hpp.42568","article-title":"Risk factors for atherosclerotic cardiovascular disease (ASCVD) in healthcare professionals of Azar Cohort Study: a cross-sectional study.","volume":"14","author":"Roshanravan","year":"2024","journal-title":"Health Promot Perspect"},{"key":"R9-20251101","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jacl.2022.05.068","article-title":"NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient.","volume":"16","author":"Cheeley","year":"2022","journal-title":"J Clin Lipidol"},{"key":"R10-20251101","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18773\/austprescr.2016.060","article-title":"Experimental and clinical pharmacology: PCSK9 inhibitors - mechanisms of action.","volume":"39","author":"Page","year":"2016","journal-title":"Aust Prescr"},{"key":"R11-20251101","doi-asserted-by":"crossref","first-page":"130","DOI":"10.21037\/atm.2018.02.20","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibition with evolocumab: powerful low-density lipoprotein cholesterol (LDL-C) lowering and improved cardiovascular outcomes without an increase in the risk of diabetes mellitus.","volume":"6","author":"Kosmas","year":"2018","journal-title":"Ann Transl Med"},{"key":"R12-20251101","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes.","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"R13-20251101","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.3390\/cells11192972","article-title":"PCSK9 inhibition: from current advances to evolving future.","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"R14-20251101","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome.","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"R15-20251101","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease.","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"R16-20251101","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.atherosclerosis.2018.06.002","article-title":"Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study.","volume":"277","author":"Ballantyne","year":"2018","journal-title":"Atherosclerosis"},{"key":"R17-20251101","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients.","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"R18-20251101","doi-asserted-by":"crossref","first-page":"100371","DOI":"10.1016\/j.ajpc.2022.100371","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: a review of current practice and recommendations for improved effectiveness.","volume":"12","author":"Makover","year":"2022","journal-title":"Am J Prev Cardiol"},{"key":"R19-20251101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vph.2016.05.013","article-title":"Physiology and pathophysiology of oxLDL uptake by vascular wall cells in atherosclerosis.","volume":"84","author":"Di Pietro","year":"2016","journal-title":"Vascul Pharmacol"},{"key":"R20-20251101","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.3390\/ijms20143561","article-title":"The atherogenic role of circulating modified lipids in atherosclerosis.","volume":"20","author":"Summerhill","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R21-20251101","doi-asserted-by":"crossref","first-page":"584","DOI":"10.3390\/cells9030584","article-title":"Signaling pathways and key genes involved in regulation of foam cell formation in atherosclerosis.","volume":"9","author":"Poznyak","year":"2020","journal-title":"Cells"},{"key":"R22-20251101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/ijms24010075","article-title":"Lipids in atherosclerosis: pathophysiology and the role of calculated lipid indices in assessing cardiovascular risk in patients with hyperlipidemia.","volume":"24","author":"Gaggini","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R23-20251101","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3390\/biom9080301","article-title":"Antioxidants and atherosclerosis: mechanistic aspects.","volume":"9","author":"Malekmohammad","year":"2019","journal-title":"Biomolecules"},{"key":"R24-20251101","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41419-023-06206-z","article-title":"Macrophage polarization and metabolism in atherosclerosis.","volume":"14","author":"Hou","year":"2023","journal-title":"Cell Death Dis"},{"key":"R25-20251101","doi-asserted-by":"crossref","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","article-title":"Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation.","volume":"284","author":"Poirier","year":"2009","journal-title":"J Biol Chem"},{"key":"R26-20251101","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"R27-20251101","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 revolution: current status, controversies, and future directions.","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc Med"},{"key":"R28-20251101","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"R29-20251101","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"R30-20251101","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jacl.2014.07.001","article-title":"Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease.","volume":"8","author":"Zhang","year":"2014","journal-title":"J Clin Lipidol"},{"key":"R31-20251101","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s11883-024-01230-6","article-title":"PCSK9 and coronary artery plaque\u2014new opportunity or red herring?","volume":"26","author":"Barbieri","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"R32-20251101","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1194\/jlr.P071704","article-title":"Effect of evolocumab on cholesterol synthesis and absorption.","volume":"57","author":"Peach","year":"2016","journal-title":"J Lipid Res"},{"key":"R33-20251101","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/cpt.1193","article-title":"Adverse events associated with PCSK 9 inhibitors: a real\u2010world experience.","volume":"105","author":"G\u00fcrg\u00f6ze","year":"2019","journal-title":"Clin Pharma Therapeutics"},{"key":"R34-20251101","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries.","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"key":"R35-20251101","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study.","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"R36-20251101","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study.","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"R37-20251101","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurjpc\/zwaa097","article-title":"Safety and efficacy of alirocumab in a real-life setting: the ODYSSEY APPRISE study.","volume":"28","author":"Gaudet","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"R38-20251101","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.122.062557","article-title":"Alirocumab and coronary atherosclerosis in asymptomatic patients with familial hypercholesterolemia: the architect study.","volume":"147","author":"P\u00e9rez De Isla","year":"2023","journal-title":"Circulation"},{"key":"R39-20251101","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"R40-20251101","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.amjcard.2017.06.023","article-title":"Efficacy and safety of alirocumab versus ezetimibe over 2 years (from ODYSSEY COMBO II).","volume":"120","author":"El Shahawy","year":"2017","journal-title":"Am J Cardiol"},{"key":"R41-20251101","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.ahj.2015.03.004","article-title":"Efficacy and safety of the proprotein convertase subtilisin\/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study.","volume":"169","author":"Kereiakes","year":"2015","journal-title":"Am Heart J"},{"key":"R42-20251101","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"R43-20251101","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","article-title":"Long-term evolocumab in patients with established atherosclerotic cardiovascular disease.","volume":"146","author":"O\u2019Donoghue","year":"2022","journal-title":"Circulation"},{"issue":"Supplement_2","key":"R44-20251101","doi-asserted-by":"crossref","first-page":"ehad655.2808","DOI":"10.1093\/eurheartj\/ehad655.2808","article-title":"Longer-term impact of PCSK9 inhibitors on major adverse cardiovascular events and all-cause mortality: a systematic review and meta-analysis of randomised controlled trials.","volume":"44","author":"Grover","year":"2023","journal-title":"Eur Heart J"},{"key":"R45-20251101","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1536\/ihj.22-052","article-title":"Effect of the early application of evolocumab on blood lipid profile and cardiovascular prognosis in patients with extremely high-risk acute coronary syndrome.","volume":"63","author":"Hao","year":"2022","journal-title":"Int Heart J"},{"key":"R46-20251101","doi-asserted-by":"crossref","first-page":"e888","DOI":"10.4244\/EIJ-D-22-00735","article-title":"Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.","volume":"18","author":"Mehta","year":"2022","journal-title":"EuroIntervention"},{"key":"R47-20251101","doi-asserted-by":"crossref","first-page":"e647","DOI":"10.4244\/EIJ-D-22-00269","article-title":"Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial.","volume":"18","author":"Ishihara","year":"2022","journal-title":"EuroIntervention"},{"key":"R48-20251101","doi-asserted-by":"crossref","first-page":"6721","DOI":"10.3390\/ijerph20186721","article-title":"Lipoprotein(a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives.","volume":"20","author":"Vinci","year":"2023","journal-title":"Int J Environ Res Public Health"},{"key":"R49-20251101","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","article-title":"Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"R50-20251101","first-page":"153","article-title":"Effect of early initiation of evolocumab on lipoprotein(a) in patients with acute myocardial infarction: sub-analysis of a randomized controlled trial.","volume":"9","author":"Okada","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"R51-20251101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2022.01.058","article-title":"The trajectory of lipoprotein(a) during the peri- and early postinfarction period and the impact of proprotein convertase subtilisin\/kexin type 9 inhibition.","volume":"171","author":"Vavuranakis","year":"2022","journal-title":"Am J Cardiol"},{"key":"R52-20251101","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1253\/circj.CJ-19-0412","article-title":"Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndrome \u2015 the Odyssey J-IVUS trial.","volume":"83","author":"Ako","year":"2019","journal-title":"Circ J"},{"key":"R53-20251101","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2021.05.008","article-title":"Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: a time course study.","volume":"327","author":"Lepor","year":"2021","journal-title":"Atherosclerosis"},{"key":"R54-20251101","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial.","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"R55-20251101","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction.","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"key":"R57-20251101","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/jamacardio.2024.3200","article-title":"Lesion-level effects of LDL\u2013C\u2013lowering therapy in patients with acute myocardial infarction: a post hoc analysis of the PACMAN-AMI trial.","volume":"9","author":"Biccir\u00e8","year":"2024","journal-title":"JAMA Cardiol"},{"key":"R58-20251101","first-page":"e011382","article-title":"Effect of evolocumab in patients with prior percutaneous coronary intervention.","volume":"15","author":"Furtado","year":"2022","journal-title":"Circ: Cardiovasc Interv"},{"key":"R59-20251101","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.jacc.2019.08.010","article-title":"Evolocumab for early reduction of LDL cholesterol levels in patients with acute coronary syndromes (EVOPACS).","volume":"74","author":"Koskinas","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R60-20251101","doi-asserted-by":"crossref","first-page":"e016683","DOI":"10.1161\/CIRCIMAGING.124.016683","article-title":"Association of lipoprotein(A) with changes in coronary atherosclerosis in patients treated with alirocumab.","volume":"17","author":"Koskinas","year":"2024","journal-title":"Circ Cardiovasc Imaging"},{"key":"R61-20251101","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial.","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"R62-20251101","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1161\/CIRCULATIONAHA.119.042551","article-title":"Risk categorization using new American College of Cardiology\/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes.","volume":"140","author":"Roe","year":"2019","journal-title":"Circulation"},{"key":"R63-20251101","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.120.049447","article-title":"Clinical efficacy and safety of alirocumab after acute coronary syndrome according to achieved level of low-density lipoprotein cholesterol: a propensity score\u2013matched analysis of the Odyssey Outcomes Trial.","volume":"143","author":"Schwartz","year":"2021","journal-title":"Circulation"},{"key":"R64-20251101","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events.","volume":"73","author":"Szarek","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"R65-20251101","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/FJC.0000000000000706","article-title":"Alirocumab in acute myocardial infarction: results from the Virginia Commonwealth University alirocumab response trial (VCU-AlirocRT).","volume":"74","author":"Trankle","year":"2019","journal-title":"J Cardiovasc Pharmacol"},{"key":"R66-20251101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1177\/2047487319864671","article-title":"Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.","volume":"27","author":"Ballantyne","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"R67-20251101","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.recesp.2024.05.004","article-title":"Efficacy and safety of bempedoic acid in acute coronary syndrome. Design of the clinical trial ES-BempeDACS.","volume":"78","author":"Raposeiras-Roub\u00edn","year":"2025","journal-title":"Rev Esp Cardiol (English ed.)"},{"key":"R68-20251101","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","article-title":"Trials and tribulations of CETP inhibitors.","volume":"122","author":"Tall","year":"2018","journal-title":"Circ Res"},{"key":"R69-20251101","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s11883-024-01231-5","article-title":"Obicetrapib\u2014the Rebirth of CETP Inhibitors?","volume":"26","author":"Chang","year":"2024","journal-title":"Curr Atheroscler Rep"},{"key":"R70-20251101","doi-asserted-by":"crossref","first-page":"100701","DOI":"10.1016\/j.ajpc.2024.100701","article-title":"Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond.","volume":"19","author":"Safarova","year":"2024","journal-title":"Am J Prev Cardiol"},{"key":"R71-20251101","first-page":"49","article-title":"Angiopoietin-like protein 3 (ANGPTL3) inhibitors in the management of refractory hypercholesterolemia.","volume":"14","author":"Kosmas","year":"2022","journal-title":"Clin Pharmacol"},{"key":"R72-20251101","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJMoa2404147","article-title":"Zodasiran, an RNAi therapeutic targeting ANGPTL3, for mixed hyperlipidemia.","volume":"391","author":"Rosenson","year":"2024","journal-title":"N Engl J Med"},{"key":"R73-20251101","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/liv.15497","article-title":"Long\u2010term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia.","volume":"43","author":"Larrey","year":"2023","journal-title":"Liver Int"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:00:29Z","timestamp":1762002029000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000001574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":72,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000001574","relation":{},"ISSN":["0954-6928","1473-5830"],"issn-type":[{"value":"0954-6928","type":"print"},{"value":"1473-5830","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"2025-04-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}